赛马鲁肽
医学
临床实习
重症监护医学
替代医学
兴奋剂
疾病
梅德林
食品药品监督管理局
药物治疗
医疗保健
代谢性疾病
最佳实践
脂肪性肝炎
药方
MRAS公司
药品
病人护理
临床试验
家庭医学
临床药理学
医学物理学
作者
Maria Mironova,Vlad Ratziu,Mary Eugenia Rinella,Meena B. Bansal,Mazen Noureddin,Naim Alkhouri,Quentin Mark Anstee,Philip Noel Newsome,Jörn Markus Schattenberg,Arun Jayant Sanyal,Rohit Seth Loomba
出处
期刊:Gut
[BMJ]
日期:2026-09-11
卷期号:: gutjnl-2026
标识
DOI:10.1136/gutjnl-2026-340031
摘要
The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy for metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis (F2-F3) without cirrhosis, a disease that previously had no available pharmacological treatment. The two agents act through complementary mechanisms: resmetirom as a liver-directed thyroid hormone receptor-beta agonist and semaglutide as a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a broad spectrum of metabolic effects. In this international expert panel review, we consolidate data from phase III trials, FDA labels and emerging clinical experience into a single resource. It covers the entire care pathway: non-invasive test-based diagnosis of MASH with significant fibrosis, treatment selection and initiation, on-treatment monitoring and response assessment. We offer practical recommendations for individualising therapy by patient phenotype, managing patients already receiving GLP-1 RAs and defining response, non-response and criteria for switching or combining agents. The proposed framework is intended to evolve as long-term outcomes data emerge and additional MASH therapies become available.
科研通智能强力驱动
Strongly Powered by AbleSci AI